Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www-thieme-connect-de.accesdistant.sorbonne-universite.fr/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2003; 23(2): 207-214
DOI: 10.1055/s-2003-41133
DOI: 10.1055/s-2003-41133
Therapy of Neurological Disorders in Systemic Vasculitis
Further Information
Publication History
Publication Date:
01 August 2003 (online)
ABSTRACT
Significant progress has been made in our understanding of the underlying cellular and molecular mechanisms associated with vasculitis. Simultaneous involvement of the nervous system and systemic organs points to shared antigenic targets or immune mechanisms operative at both sites. Although specific immunotherapy is not available, the old and new immunomodulatory therapies have been instrumental in providing effective therapy in most of these chronic autoimmune disorders. The treatment of giant cell arteritis, neurosarcoidosis, Wegener's granulomatosis, systemic lupus erythematosus, polyarteritis, Sjögren's syndrome, and Behcet disease will be reviewed.
KEYWORDS
Autoimmunity - nervous system - therapy - vasculitis
REFERENCES
- 1 Medawar P. Immunity to homologous grafted skin III: the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Path . 1948; 29 58-69
- 2 Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci . 1986; 9 271-277
- 3 Janeway C A, Travers P, Walport M, Shlomchik M J. Immunobiology: The Immune System in Health and Disease. New York: Churchill Livingstone 2001
MissingFormLabel
- 4 Vincent A, Martino G. Autoantibodies in Neurological Diseases. 1st ed. Milano: Springer Verlag Italia 2002
MissingFormLabel
- 5 Lehmann P V, Forsthuber T, Miller A, Sercarz E E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature . 1992; 358 155-157
- 6 Harper L, Ren Y, Savill J, Adu D, Savage C O. Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages. Am J Pathol . 2000; 157 211-220
- 7 Harper L, Savage C O. Leukocyte-endothelial interactions in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Rheum Dis Clin North Am . 2001; 27 887-903
- 8 Gold R, Buttgereit F, Toyka K V. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol . 2001; 117 1-8
- 9 Dalakas M C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve . 1999; 22 1479-1497
- 10 Salvarani C, Cantini F, Boiardi L, Hunder G G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med . 2002; 347 261-271
- 11 LeVine S M, Hellmann D B. Giant cell arteritis. Curr Opin Rheumatol . 2002; 14 3-10
- 12 Jover J A, Hernandez-Garcia C, Morado I C, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med . 2001; 134 106-114
- 13 Hoffman G S, Cid M C, Hellmann D B. et al . A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum . 2002; 46 1309-1318
- 14 Gullapalli D, Phillips L H. Neurologic manifestations of sarcoidosis. Neurol Clin . 2002; 20 59-83
- 15 Nowak D A, Widenka D C. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol . 2001; 248 363-372
- 16 Ferriby D, De Seze J, Stojkovic T. et al . Long-term follow-up of neurosarcoidosis. Neurology . 2001; 57 927-929
- 17 Ferriby D, De Seze J, Stojkovic T. et al . Clinical manifestations and therapeutic approach in neurosarcoidosis [in French]. Rev Neurol (Paris) . 2000; 156 965-975
- 18 Agbogu B N, Stern B J, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol . 1995; 52 875-879
- 19 Leavitt R Y, Fauci A S, Bloch D A. et al . The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum . 1990; 33 1101-1107
- 20 Hoffman G S, Kerr G S, Leavitt R Y. et al . Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med . 1992; 116 488-498
- 21 De Groot K, Adu D, Savage C O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant . 2001; 16 2018-2027
- 22 Jayne D R, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc . 1997; 72 737-747
- 23 Langford C A, Talar-Williams C, Barron K S, Sneller M C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum . 1999; 42 2666-2673
- 24 Hoffman G S, Leavitt R Y, Kerr G S, Fauci A S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum . 1992; 35 1322-1329
- 25 Stegeman C A, Tervaert J W, de Jong E P, Kallenberg C G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med . 1996; 335 16-20
- 26 Lightfoot Jr W R, Michel B A, Bloch D A. et al . The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum . 1990; 33 1088-1093
- 27 Genereau T, Lortholary O, Leclerq P. et al . Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br J Rheumatol . 1994; 33 959-962
- 28 Brey R L, Holliday S L, Saklad A R. et al . Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology . 2002; 58 1214-1220
- 29 Kimberly R P. Treatment: corticosteroids and anti-inflammatory drugs. Rheum Dis Clin North Am . 1988; 14 203-221
- 30 Houssiau F A, Vasconcelos C, D'Cruz D. et al . Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum . 2002; 46 2121-2131
- 31 Drosos A A, Andonopoulos A P, Costopoulos J S, Papadimitriou C S, Moutsopoulos H M. Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol . 1988; 27 123-127
- 32 Vitali C, Bencivelli W, Isenberg D A. et al . Disease activity in systemic lupus erythematosus-report of the Consensus Study Group of the European Workshop for Rheumatology Research I: a descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol . 1992; 10 527-539
- 33 Caroyer J M, Manto M U, Steinfeld S D. Severe sensory neuronopathy responsive to infliximab in primary Sjögren's syndrome. Neurology . 2002; 59 1113-1114
- 34 Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol . 1982; 100 1455-1458
- 35 Yazici H, Pazarli H, Barnes C G. et al . A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med . 1990; 322 281-285